Chan, A. W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., … Moher, D. (2017). SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Japanese Pharmacology and Therapeutics, 45(12), 1895–1904.

Chan, A. W., J. M. Tetzlaff, D. G. Altman, A. Laupacis, P. C. Gøtzsche, K. Krleža-Jerić, A. Hróbjartsson, et al. “SPIRIT 2013 statement: Defining standard protocol items for clinical trials.” Japanese Pharmacology and Therapeutics 45, no. 12 (January 1, 2017): 1895–1904.

Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Japanese Pharmacology and Therapeutics. 2017 Jan 1;45(12):1895–904.

Chan, A. W., et al. “SPIRIT 2013 statement: Defining standard protocol items for clinical trials.” Japanese Pharmacology and Therapeutics, vol. 45, no. 12, Jan. 2017, pp. 1895–904.

Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie M, Moher D. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Japanese Pharmacology and Therapeutics. 2017 Jan 1;45(12):1895–1904.